Log in

NASDAQ:KITEKite Pharma Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$179.79
0.00 (0.00 %)
(As of 10/19/2017)
Add
Today's Range
$179.79
Now: $179.79
$179.79
50-Day Range N/A
52-Week Range
$39.82
Now: $179.79
$179.99
VolumeN/A
Average Volume1.65 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).
Read More
Kite Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.86 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:KITE
CUSIPN/A
Phone+1-310-8249999

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableOptionable

Receive KITE News and Ratings via Email

Sign-up to receive the latest news and ratings for KITE and its competitors with MarketBeat's FREE daily newsletter.

Kite Pharma (NASDAQ:KITE) Frequently Asked Questions

How were Kite Pharma's earnings last quarter?

Kite Pharma Inc (NASDAQ:KITE) issued its earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.75) by $0.05. The biopharmaceutical company earned $4.90 million during the quarter, compared to analyst estimates of $5.74 million. The company's quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.54) EPS. View Kite Pharma's earnings history.

Has Kite Pharma been receiving favorable news coverage?

Headlines about KITE stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kite Pharma earned a daily sentiment score of -3.2 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Kite Pharma.

What other stocks do shareholders of Kite Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kite Pharma investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Continental (UAL), Juno Therapeutics (JUNO), bluebird bio (BLUE) and Array Biopharma (ARRY).

Who are Kite Pharma's key executives?

Kite Pharma's management team includes the following people:
  • Arie S. Belldegrun, Executive Chairman of the Board, President, Chief Executive Officer, Founder
  • Paul L. Jenkinson, Chief Financial Officer
  • Cynthia M. Butitta, Chief Operating Officer
  • David Chang M.D. Ph.D., Executive Vice President - Research and Development, Chief Medical Officer
  • Helen S. Kim, Executive Vice President - Business Development
  • Timothy L. Moore, Executive Vice President - Technical Operations
  • Christine Cassiano, Senior Vice President - Corporate Communications and Investor Relations
  • , Bio & Compensation - 
  • Jian Irish Ph.D., Senior Vice President - Supply Chain
  • , Bio & Compensation - 
  • Jeffrey Wiezorek M.D., Senior Vice President - Clinical Development
  • Shawn Cline Tomasello, Chief Commercial Officer

What is Kite Pharma's stock symbol?

Kite Pharma trades on the NASDAQ under the ticker symbol "KITE."

What is Kite Pharma's stock price today?

One share of KITE stock can currently be purchased for approximately $179.79.

What is Kite Pharma's official website?

The official website for Kite Pharma is www.kitepharma.com.

How can I contact Kite Pharma?

Kite Pharma's mailing address is 2225 Colorado Ave, SANTA MONICA, CA 90404-3505, United States. The biopharmaceutical company can be reached via phone at +1-310-8249999.

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.